Revenue Growth in Core Business
Evome generated $10.5 million in revenue for Q2 2024, with $6.1 million from the core business, Biodex Rehab. This represents a 59% revenue growth compared to Q1 2024.
Positive Adjusted EBITDA
Evome posted a positive adjusted EBITDA of $421,000 in Q2 2024, marking an improvement of $1.7 million over Q1 2024 and $1.4 million year-over-year compared to Q2 2023.
Debt Reduction
Evome reduced its debt by $2.7 million in Q2 2024, including $2.6 million from acquisition debt and $200,000 from the company's credit line. An additional reduction of $900,000 to the credit line was paid down in July 2024.
Strong Cash Position
Evome ended Q2 2024 with over $1 million in cash on hand, indicating improved liquidity compared to previous quarters.
White Labeling Strategy for Growth
Evome plans to expand the Biodex brand through a white labeling strategy, enabling it to offer new products without significant capital expenditure, which is expected to generate additional revenue in 2025.